Therapeutic antibodies are an essential and rapidly expanding drug modality.

Cross-domain retrieval (CDR) is finding increasingly broad applications across various domains. However, existing efforts have several major limitations, with the most critical being their reliance on accurate supervision. Recent studies thus focus on achieving unsupervised CDR, but they typically assume that the category spaces across domains are identical, an assumption that is often unrealistic in real-world scenarios. This is because only through dedicated and comprehensive analysis can the category composition of a data domain be obtained, which contradicts the premise of unsupervised scenarios.

Clinical decision-making is inherently complex and fast-paced, particularly in emergency departments (EDs) where critical, rapid and high-stakes decisions are made. Clinical Decision Rules (CDRs) are standardized evidence-based tools that combine signs, symptoms, and clinical variables into decision trees to make consistent and accurate diagnoses. CDR usage is often hindered by the clinician's cognitive load, limiting their ability to quickly recall and apply the appropriate rules. We introduce CDR-Agent, a novel LLM-based system designed to enhance ED decision-making by autonomously identifying and applying the most appropriate CDRs based on unstructured clinical notes. To validate CDR-Agent, we curated two novel ED datasets: synthetic and CDR-Bench, although CDR-Agent is applicable to non ED clinics. CDR-Agent achieves a 56.3\% (synthetic) and 8.7\% (CDR-Bench) accuracy gain relative to the standalone LLM baseline in CDR selection. Moreover, CDR-Agent significantly reduces computational overhead. Using these datasets, we demonstrated that CDR-Agent not only selects relevant CDRs efficiently, but makes cautious yet effective imaging decisions by minimizing unnecessary interventions while successfully identifying most positively diagnosed cases, outperforming traditional LLM prompting approaches. Code for our work can be found at: https://github.com/zhenxianglance/medagent-cdr-agent

Computational antibody design holds immense promise for therapeutic discovery, yet existing generative models are fundamentally limited by two core challenges: (i) a lack of dynamical consistency, which yields physically implausible structures, and (ii) poor generalization due to data scarcity and structural bias. We introduce FP-AbDiff, the first antibody generator to enforce Fokker-Planck Equation (FPE) physics along the entire generative trajectory. Our method minimizes a novel FPE residual loss over the mixed manifold of CDR geometries (R^3 x SO(3)), compelling locally-learned denoising scores to assemble into a globally coherent probability flow. This physics-informed regularizer is synergistically integrated with deep biological priors within a state-of-the-art SE(3)-equivariant diffusion framework. Rigorous evaluation on the RAbD benchmark confirms that FP-AbDiff establishes a new state-of-the-art. In de novo CDR-H3 design, it achieves a mean Root Mean Square Deviation of 0.99 Å when superposing on the variable region, a 25% improvement over the previous state-of-the-art model, AbX, and the highest reported Contact Amino Acid Recovery of 39.91%. This superiority is underscored in the more challenging six-CDR co-design task, where our model delivers consistently superior geometric precision, cutting the average full-chain Root Mean Square Deviation by ~15%, and crucially, achieves the highest full-chain Amino Acid Recovery on the functionally dominant CDR-H3 loop (45.67%). By aligning generative dynamics with physical laws, FP-AbDiff enhances robustness and generalizability, establishing a principled approach for physically faithful and functionally viable antibody design.

As the global burden of Alzheimer's disease (AD) continues to grow, early and accurate detection has become increasingly critical, especially in regions with limited access to advanced diagnostic tools. We propose BRAINS (Biomedical Retrieval-Augmented Intelligence for Neurodegeneration Screening) to address this challenge. This novel system harnesses the powerful reasoning capabilities of Large Language Models (LLMs) for Alzheimer's detection and monitoring. BRAINS features a dual-module architecture: a cognitive diagnostic module and a case-retrieval module. The Diagnostic Module utilizes LLMs fine-tuned on cognitive and neuroimaging datasets -- including MMSE, CDR scores, and brain volume metrics -- to perform structured assessments of Alzheimer's risk. Meanwhile, the Case Retrieval Module encodes patient profiles into latent representations and retrieves similar cases from a curated knowledge base. These auxiliary cases are fused with the input profile via a Case Fusion Layer to enhance contextual understanding. The combined representation is then processed with clinical prompts for inference. Evaluations on real-world datasets demonstrate BRAINS effectiveness in classifying disease severity and identifying early signs of cognitive decline. This system not only shows strong potential as an assistive tool for scalable, explainable, and early-stage Alzheimer's disease detection, but also offers hope for future applications in the field.

Existing EEG-based methods are limited by full-band frequency analysis that hinders precise differentiation of dementia subtypes and severity stages. We propose a variational mixture of graph neural experts (VMoGE) that integrates frequency-specific biomarker identification with structured variational inference for enhanced dementia diagnosis and staging. VMoGE employs a multi-granularity transformer to extract multi-scale temporal patterns across four frequency bands, followed by a variational graph convolutional encoder using Gaussian Markov Random Field priors. Through structured variational inference and adaptive gating, VMoGE links neural specialization to physiologically meaningful EEG frequency bands. Evaluated on two diverse datasets for both subtype classification and severity staging, VMoGE achieves superior performance with AUC improvements of +4% to +10% over state-of-the-art methods. Moreover, VMoGE provides interpretable insights through expert weights that correlate with clinical indicators and spatial patterns aligned with neuropathological signatures, facilitating EEG biomarker discovery for comprehensive dementia diagnosis and monitoring.

Antibody design remains a critical challenge in therapeutic and diagnostic development, particularly for complex antigens with diverse binding interfaces. Current computational methods face two main limitations: (1) capturing geometric features while preserving symmetries, and (2) generalizing novel antigen interfaces. Despite recent advancements, these methods often fail to accurately capture molecular interactions and maintain structural integrity. To address these challenges, we propose \textbf{AbMEGD}, an end-to-end framework integrating \textbf{M}ulti-scale \textbf{E}quivariant \textbf{G}raph \textbf{D}iffusion for antibody sequence and structure co-design. Leveraging advanced geometric deep learning, AbMEGD combines atomic-level geometric features with residue-level embeddings, capturing local atomic details and global sequence-structure interactions. Its E(3)-equivariant diffusion method ensures geometric precision, computational efficiency, and robust generalizability for complex antigens. Furthermore, experiments using the SAbDab database demonstrate a 10.13\% increase in amino acid recovery, 3.32\% rise in improvement percentage, and a 0.062~Å reduction in root mean square deviation within the critical CDR-H3 region compared to DiffAb, a leading antibody design model. These results highlight AbMEGD's ability to balance structural integrity with improved functionality, establishing a new benchmark for sequence-structure co-design and affinity optimization. The code is available at: https://github.com/Patrick221215/AbMEGD.